Faes Farma SA (FAE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Faes Farma SA (FAE) has a cash flow conversion efficiency ratio of 0.048x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€35.56 Million ≈ $41.57 Million USD) by net assets (€747.70 Million ≈ $874.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review Faes Farma SA (FAE) flexibility index to assess the company's free cash flow relative to its total liabilities.
Faes Farma SA - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Faes Farma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Faes Farma SA market capitalisation for the company's overall valuation and market capitalisation.
Faes Farma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Faes Farma SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hubei Wanrun New Energy Technology Co. Ltd. A
SHG:688275
|
N/A |
|
Globant SA
F:2G2
|
0.079x |
|
Ventive Hospitality Ltd
NSE:VENTIVE
|
0.052x |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
0.018x |
|
Anupam Rasayan India Limited
NSE:ANURAS
|
0.012x |
|
Sociedad Matriz SAAM SA
SN:SMSAAM
|
-0.031x |
|
Healthcare Services Group Inc
NASDAQ:HCSG
|
0.085x |
|
Inno Laser Technology Co. Ltd.
SHE:301021
|
0.000x |
Annual Cash Flow Conversion Efficiency for Faes Farma SA (2005–2025)
The table below shows the annual cash flow conversion efficiency of Faes Farma SA from 2005 to 2025. View today's stock price for Faes Farma SA for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €747.70 Million ≈ $874.14 Million |
€78.49 Million ≈ $91.76 Million |
0.105x | -33.94% |
| 2024-12-31 | €726.62 Million ≈ $849.49 Million |
€115.47 Million ≈ $134.99 Million |
0.159x | +4.40% |
| 2023-12-31 | €663.35 Million ≈ $775.52 Million |
€100.97 Million ≈ $118.04 Million |
0.152x | -14.15% |
| 2022-12-31 | €602.28 Million ≈ $704.13 Million |
€106.79 Million ≈ $124.85 Million |
0.177x | +19.78% |
| 2021-12-31 | €538.07 Million ≈ $629.06 Million |
€79.64 Million ≈ $93.11 Million |
0.148x | -10.82% |
| 2020-12-31 | €472.88 Million ≈ $552.84 Million |
€78.49 Million ≈ $91.76 Million |
0.166x | +1.59% |
| 2019-12-31 | €413.65 Million ≈ $483.60 Million |
€67.58 Million ≈ $79.01 Million |
0.163x | -0.83% |
| 2018-12-31 | €360.15 Million ≈ $421.06 Million |
€59.34 Million ≈ $69.37 Million |
0.165x | +26.65% |
| 2017-12-31 | €320.77 Million ≈ $375.02 Million |
€41.73 Million ≈ $48.78 Million |
0.130x | -25.32% |
| 2016-12-31 | €284.89 Million ≈ $333.06 Million |
€49.62 Million ≈ $58.02 Million |
0.174x | +8.29% |
| 2015-12-31 | €254.34 Million ≈ $297.34 Million |
€40.91 Million ≈ $47.83 Million |
0.161x | +14.00% |
| 2014-12-31 | €228.63 Million ≈ $267.29 Million |
€32.26 Million ≈ $37.71 Million |
0.141x | -11.81% |
| 2013-12-31 | €197.81 Million ≈ $231.26 Million |
€31.65 Million ≈ $37.00 Million |
0.160x | +23.86% |
| 2012-12-31 | €184.82 Million ≈ $216.07 Million |
€23.87 Million ≈ $27.91 Million |
0.129x | +8.38% |
| 2011-12-31 | €167.61 Million ≈ $195.96 Million |
€19.98 Million ≈ $23.35 Million |
0.119x | +29.44% |
| 2010-12-31 | €165.51 Million ≈ $193.50 Million |
€15.24 Million ≈ $17.81 Million |
0.092x | -33.21% |
| 2009-12-31 | €122.93 Million ≈ $143.71 Million |
€16.95 Million ≈ $19.81 Million |
0.138x | -37.03% |
| 2008-12-31 | €156.71 Million ≈ $183.21 Million |
€34.31 Million ≈ $40.11 Million |
0.219x | +153.53% |
| 2007-12-31 | €151.06 Million ≈ $176.60 Million |
€13.04 Million ≈ $15.25 Million |
0.086x | -39.41% |
| 2006-12-31 | €139.85 Million ≈ $163.50 Million |
€19.93 Million ≈ $23.30 Million |
0.143x | +40.54% |
| 2005-12-31 | €131.62 Million ≈ $153.88 Million |
€13.35 Million ≈ $15.60 Million |
0.101x | -- |
About Faes Farma SA
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants servic… Read more